irinotecan has been researched along with 7-hydroxystaurosporine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Saijo, N | 1 |
| Brown, MK; Eastman, A; Kohn, EA; Livingstone, M; Ruth, ND | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Schwartz, GK; Tse, AN | 1 |
| Bresnick, E; Eastman, A; Kohn, EA; Levesque, AA | 1 |
| Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA | 1 |
| Eastman, A; Fanous, AA; Levesque, AA; Poh, A | 1 |
| Adkins, DR; Arquette, MA; Cai, SR; Chen, RC; Creekmore, AN; Dancey, J; Ellis, MJ; Fleshman, JW; Fracasso, PM; Goodner, SA; Guo, Z; Lin, L; Ma, CX; McLeod, HL; Naughton, MJ; Picus, J; Piwnica-Worms, H; Pluard, TJ; Rader, JS; Rudek, MA; Ryan, CE; Soares, EM; Tan, BR; Tao, Y; Williams, KJ; Wright, LP | 1 |
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Aft, RL; Cai, S; Ellis, MJ; Goiffon, RJ; Guo, Z; Hoog, J; Li, S; Lin, L; Ma, CX; Piwnica-Worms, H; Prat, A; Ryan, CE; Schaiff, WT | 1 |
| Bernard, PS; Brenin, CM; Cai, SR; Craig Lockhart, A; Creekmore, AN; Dancey, J; Doyle, LA; Ebbert, M; Ellis, MJ; Fracasso, PM; Guo, Z; Ma, CX; Mwandoro, T; Naughton, MJ; Petroni, GR; Picus, J; Piwnica-Worms, H; Pluard, TJ; Reed, J; Ryan, CE; Watson, M; Yarde, ER | 1 |
| Biffoni, M; Buccarelli, M; Cappellari, M; De Luca, G; Fanciulli, M; Goeman, F; Melucci, E; Pilozzi, E; Ricci-Vitiani, L; Signore, M | 1 |
| Angeles, C; Enzor, LA; Levesque, AA; Pappalardo, RM; Puli, P | 1 |
1 review(s) available for irinotecan and 7-hydroxystaurosporine
| Article | Year |
|---|---|
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
3 trial(s) available for irinotecan and 7-hydroxystaurosporine
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Topoisomerase I Inhibitors | 2008 |
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Young Adult | 2011 |
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Genes, p53; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mutation; Ribosomal Protein S6; Staurosporine; Treatment Outcome | 2013 |
10 other study(ies) available for irinotecan and 7-hydroxystaurosporine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.
Topics: Alkaloids; Breast; Camptothecin; cdc25 Phosphatases; Cell Cycle Proteins; Cell Death; Cells, Cultured; Cyclin A; Cyclin B; DNA Damage; Enzyme Inhibitors; Female; G1 Phase; Genes, cdc; Humans; Irinotecan; Kinetics; Mitosis; Protein Serine-Threonine Kinases; S Phase; Staurosporine; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastroph
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Damage; DNA Replication; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; G2 Phase; HCT116 Cells; Humans; Irinotecan; Microscopy, Fluorescence; Mitosis; S Phase; Staurosporine; Topoisomerase I Inhibitors; Transfection; Tumor Suppressor Protein p53 | 2004 |
Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints.
Topics: Camptothecin; cdc25 Phosphatases; Cell Line, Tumor; Cyclin B; DNA Damage; Female; G2 Phase; Humans; Irinotecan; Repressor Proteins; S Phase; Staurosporine; Transcriptional Activation; Tumor Suppressor Protein p53 | 2005 |
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Topics: Camptothecin; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA, Neoplasm; Female; Genes, cdc; Genes, erbB-2; Genes, p53; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Receptors, Progesterone; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; DNA Damage; Drug Synergism; HCT116 Cells; Humans; Irinotecan; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays | 2016 |
p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Damage; DNA, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; Staurosporine; Topoisomerase I Inhibitors | 2022 |